Adjusted financial outlook for 2022
September 25 2022 - 3:09PM
Adjusted financial outlook for 2022
Orphazyme A/SCompany
announcement No. 35/2022
www.orphazyme.comCompany Registration No.
32266355
Copenhagen,
Denmark, September
25,
2022 – Orphazyme A/S (ORPHA.CO)
(the “Company”) has decided to adjust its outlook for 2022, as
published on June 7, 2022. The change is driven by the separation
of activities into continuing and discontinued operations. The
discontinued activities are related to the sale of assets to
KemPharm A/S. The continuing business activities are the limited
ongoing operational business activities with only two employees.
For the full-year 2022, we anticipate a loss from continuing
operations in the range DKK 40 – 45 million and a positive result
from discontinued operations relating to the Sale of Assets to
KemPharm of DKK 87.4 million (previously operating profit in the
range DKK 10 – 30 million). As previously communicated, we expect
to end 2022 with more than DKK 30 million in cash and
equivalents.
For additional information, please
contact
Orphazyme
A/S
Anders Vadsholt, Chief Executive Officer and
Chief Financial Officer +45 28 98 90 55
Forward-looking statementThis
company announcement may contain certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including in respect of the company’s anticipated
operating plans and performance, financial position and ability to
operate as a going concern. Although the Company believes its
expectations are based on reasonable assumptions, all statements
other than statements of historical fact included in this company
announcement about future events are subject to (i) change without
notice and (ii) factors beyond the Company’s control, including
actions by regulatory agencies, effects of the global COVID-19
pandemic, and the impact of the Company’s Sale of Assets. These
statements may include, without limitation, any statements preceded
by, followed by, or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,”
“could”, and other words and terms of similar meaning or the
negative thereof. Forward-looking statements are subject to
inherent risks and uncertainties beyond the Company’s control that
could cause the Company’s actual results, performance, or
achievements to be materially different from the expected results,
performance, or achievements expressed or implied by such
forward-looking statements. In light of these risks and
uncertainties, and other risks and uncertainties that are described
in the Risk Factors section and other sections of the Company’s
Annual Report on Form 20-F, filed with the Securities and Exchange
Commission (SEC) on March 2, 2021, and other filings that the
Company makes with the SEC from time to time (which are available
at http://www.sec.gov), the events and circumstances discussed in
such forward-looking statements may not occur, and the Company’s
actual results could differ materially and adversely from those
anticipated or implied thereby. Although the Company’s
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by the Company. As a result, you are cautioned not
to rely on these forward-looking statements. Except as required by
law, the Company assumes no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
- 35-2022 Adjusted financial outlook for 2022
Orphazyme A/s (LSE:0CUM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Orphazyme A/s (LSE:0CUM)
Historical Stock Chart
From Aug 2023 to Aug 2024